Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;53(2):291-301.
doi: 10.1111/apt.16155. Epub 2020 Nov 7.

Root-cause analyses of missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease

Claire Gordon  1   2 , Desmond Chee  1   2 , Ben Hamilton  1   2 , Neel M Heerasing  1   2 , Peter Hendy  1   2 , Neil Chanchlani  1 , Simeng Lin  1   2 , Emma Wesley  2 , Ian R Daniels  3 , Nishanthi Silva  4 , Melanie Osborne  4 , Nicholas A Kennedy  1   2 , James R Goodhand  1   2 , Tariq Ahmad  1   2
Affiliations

Root-cause analyses of missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease

Claire Gordon et al. Aliment Pharmacol Ther. 2021 Jan.

Abstract

Background: Colonoscopic surveillance in patients with inflammatory bowel disease (IBD) leads to earlier detection of colorectal cancer (CRC) and reduces CRC-associated mortality. However, it is limited by poor adherence in practice.

Aim: To identify missed opportunities to detect IBD-associated CRC at our hospital METHODS: We undertook root-cause analyses to identify patients with missed opportunities to diagnose IBD-associated CRC. We matched patients with IBD-associated CRC to patients with CRC in the general population to identify differences in staging at diagnosis and clinical outcomes.

Results: Compared with the general population, patients with IBD were at increased risk of developing CRC (odds ratio 2.7 [95% CI 1.6-3.9], P < 0.001). The mean incidence of IBD-associated CRC between 1998 and 2019 was 165.4 (IQR 130.4-199.4) per 100 000 patients and has not changed over the last 20 years. Seventy-eight patients had IBD-associated CRC. Forty-two (54%) patients were eligible for CRC surveillance: 12% (5/42) and 10% (4/42) patients were diagnosed with CRC at an appropriately timed or overdue surveillance colonoscopy, respectively. Interval cancers occurred in 14% (6/42) of patients; 64% (27/42) of patients had a missed opportunity for colonoscopic surveillance where root-cause analyses demonstrated that 10/27 (37%) patients known to secondary care had not been offered surveillance. Four (15%) patients had a delayed diagnosis of CRC due to failure to account for previous colonoscopic findings. Seventeen (63%) patients were managed by primary care including seven patients discharged from secondary care without a surveillance plan. Matched case-control analysis did not show significant differences in cancer staging or 10-year survival outcomes.

Conclusion: The incidence of IBD-associated CRC has remained static. Two-thirds of patients eligible for colonoscopic surveillance had missed opportunities to diagnose CRC. Surveillance programmes without comprehensive and fully integrated recall systems across primary and secondary care are set to fail.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Patient flow diagram. IBD, inflammatory bowel disease; CRC, colorectal cancer; RDE, Royal Devon and Exeter Hospital; E1, Montreal Classification Extent 1 (ulcerative proctitis); L1, Montreal Classification Location 1 (terminal ileal).
FIGURE 2
FIGURE 2
Incidence of IBD‐associated and sporadic colorectal cancer (corrected for population changes year‐on‐year). CRC, colorectal cancer; IBD, inflammatory bowel disease.
FIGURE 3
FIGURE 3
Colorectal cancer survival vs controls. CRC, colorectal cancer; IBD, inflammatory bowel disease
See this image and copyright information in PMC

Comment in

References

    1. Lutgens M, Oldenburg B, Siersema PD, et al. Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease. Br J Cancer. 2009;101:1671‐1675. 10.1038/sj.bjc.6605359 - DOI - PMC - PubMed
    1. Bye WA, Ma C, Nguyen TM, Parker CE, Jairath V, East JE. Strategies for detecting colorectal cancer in patients with inflammatory bowel disease: a cochrane systematic review and meta‐analysis. Am J Gastroenterol. 2018;113:1801‐1809. 10.1038/s41395-018-0354-7 - DOI - PMC - PubMed
    1. Choi PM, Nugent FW, Schoetz DJ, Silverman ML, Haggitt RC. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology. 1993;105:418‐424. 10.1016/0016-5085(93)90715-O - DOI - PubMed
    1. Ording AG, Horváth‐Puhó E, Erichsen R, et al. Five‐year mortality in colorectal cancer patients with ulcerative colitis or Crohnʼs disease. Inflamm Bowel Dis. 2013;19:800‐805. 10.1097/MIB.0b013e3182802af7 - DOI - PubMed
    1. Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohn’s Colitis. 2013;7:982‐1018. 10.1016/j.crohns.2013.09.016 - DOI - PubMed